Adlai Nortye Biopharma Co., Ltd.
11
3
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
9.1%
1 terminated/withdrawn out of 11 trials
80.0%
-6.6% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
Role: lead
An Initial Evaluation of AN8025 in Solid Tumors
Role: lead
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Role: lead
First in Human, Dose Escalation Study of AN4005
Role: lead
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Role: lead
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
Role: lead
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Role: collaborator
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Role: lead
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Role: lead
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
Role: lead
Preoperative Radiotherapy and E7046 in Rectum Cancer
Role: lead
All 11 trials loaded